A Phase 1/2 Open-label, Multi-center Study to Evaluate the Safety and Clinical Activity of GSK5926371 in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas (B-NHL)

Status

Not yet recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-524915-36-00

Enrollment

Registered

2026-08-17

Start date

Unknown

Completion date

Unknown

Last updated

2026-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoma, Non-Hodgkin

Brief summary

Number of participants with dose limiting toxicities (DLTs), Number of participants with adverse events (AEs) or Serious adverse events (SAEs) by severity

Detailed description

Number of participants with clinically meaningful changes in laboratory parameters, vital signs, and electrocardiogram (ECG), Overall Response Rate (ORR), Maximum concentration (Cmax) of GSK5926371, Time to Cmax (Tmax) of GSK5926371, Area under the curve (AUC) of GSK5926371

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Number of participants with dose limiting toxicities (DLTs), Number of participants with adverse events (AEs) or Serious adverse events (SAEs) by severity	—

Secondary

Measure	Time frame
Number of participants with clinically meaningful changes in laboratory parameters, vital signs, and electrocardiogram (ECG), Overall Response Rate (ORR), Maximum concentration (Cmax) of GSK5926371, Time to Cmax (Tmax) of GSK5926371, Area under the curve (AUC) of GSK5926371	—

Outcome results